News

This interview with Amy Paller, MD, highlights the significance of the approval of ruxolitinib for the treatment of pediatric atopic dermatitis.

This approval by the FDA of ruxolitinib cream for children aged 2-11 years atopic dermatitis follows recent positive clinical trial findings on the treatment.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Kowdley joins Liver Lineup to discuss evolving approaches in cholestatic liver disease and recent progress in PBC.

The MACRO study provided no support for long-term clarithromycin use in patients with chronic rhinosinusitis, only supporting endoscopic sinus surgery.

AstraZeneca's Airsupra gains FDA approval for mild asthma, expanding its current label.

New findings confirm delgocitinib cream's safety and efficacy for chronic hand eczema, marking a significant advancement in treatment options.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

Tirzepatide saw improvements in A1C and body mass index, which were maintained over the 30-week trial and into the 52-week extension study.

The 2025 guideline updates previous recommendations made in the 2021 glomerular disease guideline based on recent therapeutic advances in IgAN.

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

New phase 2b data reveals temtokibart significantly improves atopic dermatitis symptoms in adult patients.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

When compared to transitions of care coordinators, MIH saw no additional benefit to either health status or 30-day hospital readmissions for postacute patients with HF.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.